# UNH Framed as a DOJ Risk and CVS Restores Zepbound Coverage in a Quiet Week - Managed Care Under Pressure - Week of June 13-20, 2026 > Managed-care podcast briefing for the week of June 13-20, 2026. The dedicated investor signal went quiet after last week's rich run, leaving two real handles: Telltales reframing UNH as a DOJ binary at ~14x trailing FCF, and CVS Caremark reversing its Zepbound exclusion under ERISA pressure, with Medicaid/ACA cost-shift read-throughs for CNC, MOH and ELV. ## Managed Care Under Pressure ### Week of June 13-20, 2026: UNH Framed as a DOJ Risk and CVS Restores Zepbound Coverage in a Quiet Week --- ## TL;DR - **Back to a quiet investor tape.** After last week's unusually rich run (the 2027 MA final rate and federal PBM reform both landed), the dedicated managed-care investor signal went dark this week. No podcast addressed the 2027 MA Rate Notice, Star ratings, V28/RADV, MA enrollment/benefit cuts, or any M&A (no Optum carveout, CVS strategic review, or Humana Medicaid-sale chatter). Still no buy-side or sell-side healthcare-investing show on tape. - **Two real handles for a book.** An AI-produced markets show reframed UNH as a "binary" rather than a value name: 14x trailing free cash flow, but the cash flow is exactly what the DOJ is probing. And CVS Caremark reversed last summer's Zepbound exclusion, restoring GLP-1 coverage after an ERISA class action, a concrete PBM-policy data point. - **Everything else was policy and clinical.** The volume was in Medicaid/ACA cost-shift (operator + provider voices on OBBBA/HR1 work requirements, enhanced-subsidy expiration) and clinical GLP-1 content, read-throughs for CNC, MOH, ELV and the GLP-1 cost curve, but no company-specific guidance. --- ## What's new **1) UNH reframed as a binary bet, not a cheap compounder.** On **Telltales, "Weekend Update - W2624" (2026-06-15)** ([listen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhqIC2s3swzB-2F9oz8zGHSi4GzfEh8RAu-2BZh2wRt03S1syyiKXqdNtJZNvVu9-2BkVxicZqbYEe-2FswD5aYlVnPNQVKKD96Q-2F1wmwHSWfujiHkOTA-3D-3DugjJ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DPb2L-2FpW1HVdYd5YwXwVzKVwbw1HQIhtGhMzO533awiJBCw3tNk0ozZLyko6WGkW-2Bna9dB6dA6-2FehdyndzLkFcNJF-2F0MbxgSrj2p7BI6ne8siqTCu6m-2FoWtCyZrLXfBLgw-3D-3D)), an AI-generated markets show (disclosed; treat as pundit, not operator), the hosts argued UNH "trades at 14 times trailing free cash flow, a 7% yield... the cheapest quality compounder in the market. Here's the problem. The thing generating the cash is exactly what the DOJ is investigating." Their framing: "you're not buying 14 times earnings, you're buying 14 times a number that's under subpoena." They flagged the sell-side split in the same fortnight, "six different shops raised their price targets, and Bank of America went the other way and cut it to neutral," and recapped the standing overhang (CEO departure, pulled full-year guidance, DOJ criminal and civil probe into whether MA diagnoses were inflated, stock down about a third from its high but rebounded near it). Why it matters: this is the only genuinely investor-framed item on tape, and it crystallizes the bear case as model risk, not multiple risk. **2) CVS Caremark restores Zepbound coverage, PBM blinks on GLP-1.** On **CareTalk: Healthcare. Unfiltered., "The Business & Science Behind the GLP-1 Boom" (2026-06-19)** ([listen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3D8SBJ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DPMeTfvC7HgUO-2FcvyQm5c521EvnuybwSwlTlNVKFAzibPRWH-2BOp3DZAMApe9o-2Bcq-2FjERB3YzrbkbpyUXS5LjpYSv7BJxP7XA10VgPxlPPDYsao4RsYcPgv42-2BksBChYTEw-3D-3D)), David Williams (President, Health Business Group) and John Driscoll (Chairman, UConn Health; healthcare operator) discussed CVS Caremark "restoring coverage of Zepbound, reversing a formulary decision from last summer that saved employers money but prompted patient anger and a class action lawsuit." Driscoll's read on the reversal: an "ERISA violations" suit over self-insured plan members' rights drove it. He also noted Lilly and Novo Nordisk "were charging 70 to 80 percent less" in Europe than the US. Why it matters: a direct Caremark formulary U-turn raises the GLP-1 cost-absorption question for CVS's pharmacy book just as employers test cash-pay and direct-to-employer bypass channels. **3) An operator quantifies the Medicaid disenrollment cost-shift.** On **Becker's Payer Issues Podcast, "Medicaid, Food as Medicine, and the Future of Coverage with Kelly Munson" (2026-06-19)** ([listen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgVWXD9YNAXQXWSy6U0WU-2BHN-2BVUfm8O1y8-2FLGo7UdxBdyvYw9baHs1OrdZiW8OXI13KknoQJNdQlNTlGUd93-2Fbe2umvb87vTIThDV9zYfXRqg-3D-3Dilat_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DPQvo5bPLf9Nq3ToHMnxDH7XKyaEaAxLkcij-2B9JFhAQ91PKqvhPwmU6lvtf-2FcSZ-2FPOP8-2FkVgPZrdAcnYSZvV7eOceByfp5n2hLT5tam-2BheV7p5Pe9-2FRCij6ubAVJoA-2BH3A-3D-3D)), Kelly Munson, President & CEO of Independence Health Group (operator; runs AmeriHealth Caritas Medicaid across 13 states plus DC, alongside local commercial/Medicare/ACA), said she is "gravely concerned" about OBBBA/HR1 work requirements and more-frequent eligibility checks: "it is often the procedural aspects and the administrative aspects where people lose coverage, not because they actually should have lost coverage." She cited Georgia and Arkansas going live with work requirements, "thousands of people drop off the rolls... who otherwise were eligible because of the admin requirements," and the cost cycle: dropped members skip meds, hit the ER, "and then the hospitals are going to come after the commercial insurers and want to increase the rates." She put ~92% of Medicaid-expansion enrollees as already working/caregiving/medically frail, and framed ACA as a "two to three year" struggle before it "evens out." Why it matters: a Medicaid-MCO operator confirming live disenrollment is the read-through for CNC, MOH and ELV's risk-pool acuity. **4) Florida hospital chief sizes the ACA subsidy cliff.** On **Data Book, "Changes: Mary Mayhew, CEO of the Florida Hospital Association" (2026-06-16)** ([listen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiV4iReSK8ASot4Yu4kqlW8Uwcgc2PunscC2jUZbCRykAyJeb-2FOfIH2HYPV9vvHhirOBA2JwVdoKOfS-2B-2B8G5mKI7PIrp1MCTNv6txeYxRltfQ-3D-3D14cb_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DNh05eQdgTJLU5pgv5K-2BzMv1qOOVHwg2ROJ5q80142i-2Bi15y8-2FJuUDodb0vRVoTCUmfo9FfpEpIcxJS5841kE5xABjUj7ob-2Baoc-2FPyZRYlUnGzMqynr-2Ffa5aOCggCD7rtQ-3D-3D)), Mayhew (provider) said HR1's failure to extend the enhanced premium tax credits could push "between 750,000 and a million Floridians" off marketplace coverage, Florida "leads the country" in marketplace enrollment, and that members already saw "over a 20% increase in uninsured" inpatient admissions between Q1 2025 and Q1 2026, "before the grace period has actually completely run out." She also warned on HR1's ratchet-down of provider taxes and supplemental/directed-payment programs. Why it matters: Florida is a core exchange market; this is a direct read-through to CNC's individual-marketplace margins and to the directed-payment (SDP) pressure on Medicaid plans. **5) GLP-1 cost stays the standing payer problem.** On **Conversations on Health Care, "GLP-1 Therapies: Where We've Been & Where We're Going" (2026-06-18)** ([listen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg3CvfsCVEXQwnp-2BYdpjv-2BxWUceoJV-2FmWwn6txZMCeEtcFpkiEHoLe7KdmjzpBNBhaDQYVhtYgbwORz2ZmqD8f2Yhg-2Fu-2B1e4epsfQNmxQhkHQ-3D-3DZTIy_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DDDot5LWOAminRTttalNy8dhMPyecDxVPW0JQruxxjAMk7YbMv8XUVpqKQZ7sKk2gUvxttLXX3m9bcr7fmaECcozn1CEUmfN04yySypjOR7zkSe6mBNXvIp2Z0Zkv0mIZw-3D-3D)), Dr. Jamy Ard noted ~110 million Americans are eligible for anti-obesity medication, that "payers, insurance companies, employers who are self-insured... are definitely very hesitant" given list prices "over $1,000 a month," and that Medicare remains "legally prohibited from paying for it." His counter: targeted coverage of the highest-savings cohorts can be cost-effective. Why it matters: the demand/cost mismatch is the through-line under every payer's specialty-Rx trend. --- ## The debate **Bull (utilization/MA funding has bottomed, margins recover into 2027 repricing):** The standing setup is intact, last week's 2027 MA final rate at roughly +2.5% and the deferral of the V28 risk-adjustment rebase to 2028 give plans a repricing runway, and a quiet news week with UNH's stock back near its highs suggests the market is not adding to the existential discount. **This week added no new bull evidence.** No operator quantified utilization improvement; no MA rate or Star follow-through hit the tape. **Bear (structurally higher trend + V28 + political/regulatory pressure = multi-year reset):** This week's tape leans bear at the margin. The Telltales framing makes UNH's cheapness a function of cash flows that may be "fiction" if the DOJ probe lands; the CVS Caremark GLP-1 reversal shows PBMs losing pricing leverage on the single fastest-growing specialty-Rx line; and operator/provider voices (Munson, Mayhew) describe a live Medicaid/ACA disenrollment cycle that shifts cost back onto commercial books. The bear's strongest near-term card remains binary regulatory/legal outcomes, not a smooth trend reset. --- ## Stocks in play - **UNH** *Bull:* 2027 risk-adjustment reprieve (rebase deferred to 2028), Optum diversification, ~14x trailing FCF / ~7% FCF yield. *Bear:* DOJ criminal and civil MA-coding probe targets the very cash engine; CEO departure and pulled FY guidance unresolved; sell-side openly split. *Next catalyst:* Q2'26 print (MLR vs. guide, any FY26 EPS reinstatement), DOJ procedural movement, state-AG follow-ons. - **CVS** *Bull:* Aetna MA leverage to the +2.5% 2027 rate and the withdrawn risk-adjustment cut. *Bear:* Caremark just reversed its Zepbound exclusion under ERISA pressure, GLP-1 cost absorption plus exposure to enacted federal PBM delinking/transparency. *Next catalyst:* Q2'26 Aetna MLR, Caremark GLP-1 economics, any strategic-review update (no chatter this week). - **HUM** *Bull:* cleanest 2027 MA leverage; benefits most from the rate reprieve. *Bear:* highest beta to the 2028 risk-adjustment rebase. *Next catalyst:* Q2'26 MLR, 2027 bid color. (No company-specific tape this week.) - **ELV** *Bull:* Carelon offset, MA rate relief. *Bear:* Medicaid work-requirement attrition and SDP cap phase-down; enhanced-subsidy cliff. *Next catalyst:* Q2'26 Medicaid/MA MLR splits. (Read-through only.) - **CNC** *Bull:* exchange margins, Medicaid acuity reset maturing. *Bear:* most exposed to the ACA enhanced-subsidy cliff (Florida-heavy marketplace) and procedural Medicaid disenrollment souring the risk pool. *Next catalyst:* Q2'26 HBR by segment. (Read-through only.) - **MOH** *Bull:* disciplined Medicaid underwriting. *Bear:* most Medicaid-levered to work requirements and SDP caps. *Next catalyst:* Q2'26 MCR, RFP wins/losses. (Read-through only.) - **CI** *Bull:* Evernorth growth; MA exit removed funding-cycle drag. *Bear:* Express Scripts inside the federal PBM delinking/transparency frame and the GLP-1 cost debate. *Next catalyst:* Q2'26 Evernorth growth, PBM rulemaking calendar. (No company-specific tape this week.) --- ## Read-throughs - **Medicaid / exchange insurers (CNC, MOH, ELV):** Munson's operator account of live disenrollment in Georgia/Arkansas, plus Mayhew's Florida data (20%+ jump in uninsured inpatient admissions, 750k-1M potential marketplace losses), point to a souring/shrinking risk pool and acuity drift, watch Q2'26 HBR/MCR commentary ([Becker's Payer Issues](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgVWXD9YNAXQXWSy6U0WU-2BHN-2BVUfm8O1y8-2FLGo7UdxBdyvYw9baHs1OrdZiW8OXI13KknoQJNdQlNTlGUd93-2Fbe2umvb87vTIThDV9zYfXRqg-3D-3D6LQ8_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DEMf7Y5YR8Lviyt1LCZnPWYYcKSUGDmC4L5mf71TqE9qFQOHOnevFYH0Og1-2BUPShonwOGUd-2FcgacsMCiqO3q0YctH2-2B5rqiCCW7rISjmVkzxq5qwJEfynDAPl7kUvo9O1Q-3D-3D); [Data Book](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiV4iReSK8ASot4Yu4kqlW8Uwcgc2PunscC2jUZbCRykAyJeb-2FOfIH2HYPV9vvHhirOBA2JwVdoKOfS-2B-2B8G5mKI7PIrp1MCTNv6txeYxRltfQ-3D-3DF3-F_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DN5UwlU9W4U2Pru-2FVPPQjsR9Mm5-2Bs-2FSWengng67jbpKGRtsS6HYgfSWoSq1mIfwphBIqW3RYCYd1sI8Np-2BNaeGXCbgmW2O-2Bpnxc4w-2Fu9DwsVKnPk4QTFX2HSGDtyXUu-2FKw-3D-3D)). - **PBMs / Optum-style services arms (CVS Caremark, CI Express Scripts, UNH Optum Rx):** The Caremark Zepbound reversal shows formulary leverage giving way to ERISA/legal and member-pressure, a margin and headline risk for the GLP-1 line across all three PBMs ([CareTalk](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3DC1mO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DPzTHFJHwEZrEl37OJRPfpiy2vFoTzjeQ9j5DsjsL8q-2F-2BcgpZj2SvCvTTVZWBpI8gg-2F-2B8Stl13u2yjT-2FuMyBNqqdaJVmKqEB2O5IKurZIy3HDjfwLYiZEnAqaYv-2FVqx3Xw-3D-3D)). - **Hospitals / providers (other side of utilization):** Mayhew framed the squeeze from the provider side, labor-and-delivery reimbursed "47 cents on the dollar of cost," labor costs +27% over three years, provider-tax/SDP cuts, i.e., cost-shift pressure that ultimately flows to commercial premiums ([Data Book](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiV4iReSK8ASot4Yu4kqlW8Uwcgc2PunscC2jUZbCRykAyJeb-2FOfIH2HYPV9vvHhirOBA2JwVdoKOfS-2B-2B8G5mKI7PIrp1MCTNv6txeYxRltfQ-3D-3Ds9AX_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DHnrsLA8XcJMiJx4DOuXmXFfOaw4pnQpHQTrVnb736F8Gmp1nMRJzt-2FhO4JQboOXwc5IyRpUFGnsH68zyGCZou0zIrHkl2pfTr5Mefp7GqcCyWndPv-2F9zGMBxgZ4o9ejxw-3D-3D)). - **GLP-1 cost exposure:** With ~110M eligible, >$1,000/month list prices, and Medicare still barred from paying, the specialty-Rx trend question stays open for every payer; the Caremark reversal raises near-term cost, while targeted-coverage economics remain unproven at scale ([Conversations on Health Care](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg3CvfsCVEXQwnp-2BYdpjv-2BxWUceoJV-2FmWwn6txZMCeEtcFpkiEHoLe7KdmjzpBNBhaDQYVhtYgbwORz2ZmqD8f2Yhg-2Fu-2B1e4epsfQNmxQhkHQ-3D-3DiOW0_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DLXdeE9od9l-2BvaGEe-2FrE3DT7y-2Fg6Br7V5nHkiVbsu1kWEOJIIHVdqHr-2BZRTyLdiwWEj0A1WOVh1rSXuSuDDOhsXwn-2BGnJUYY-2Fp7oatn8JANLNgOI9ZG3S2DEzmuJ6-2FYnrg-3D-3D); [CareTalk](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3DZ1LR_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbU-2FpmNHhIDuuXAvUaWfXXIDu5Qqws8HUS3f4Dosdy10DPauRqjZlFufO66sV29n2eSKkEywzSqBk-2FEVxoWl7geN55klWvThHogDNp08T6KeCjKDmsHFrGSVwSEDILvLHJuP3ciGLgAkZmxesY1qIyAzIOOJloJhGWFRdoHZlm-2FpBg-3D-3D)). --- ## What changed vs. last week Last week (week of June 13) was the **richest tape in over a month**, the CMS 2027 MA final rate (~+2.5%, V28 rebase rolled to 2028) decoded by an Optum actuary, enacted federal PBM reform under the 2026 Consolidated Appropriations Act, granular Medicaid HR1 detail, and the Massachusetts coding suit against UnitedHealthcare. **This week reverted to a quiet investor tape.** The MA-rate leg, the PBM-reform leg, Star-ratings, V28/RADV, and the Massachusetts/coding-suit thread were all **silent**, no follow-on sell-side or buy-side commentary on the 2027 rate, and no new state-AG action surfaced. What did move forward: the **UNH DOJ overhang** got a fresh, explicitly investor-framed treatment (the "14x a number under subpoena" valuation lens, plus the noted sell-side split). And a **new, concrete PBM data point** appeared, CVS Caremark's reversal of its summer Zepbound exclusion under ERISA pressure, which last week's PBM-reform discussion did not include. The Medicaid work-requirement theme also progressed from policy projection toward operator-confirmed live disenrollment (Georgia/Arkansas). Still absent, two weeks running: any dedicated buy-side/sell-side healthcare-investing podcast, and any M&A/strategic-review chatter (Optum carveout, CVS review, Humana Medicaid sale).